These could include targeted in vitro and in vivo perturbation experiments of NR4A2 and other regulators with sex-dependent activity, such as CA2 and EFNA1, to investigate their impact on PD molecular phenotypes in disease models for both males and females. The gene discussed is EFNA1; the disease is Parkinson disease.